Detalles de la búsqueda
1.
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(9): 829-838, 2017 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-28586279
2.
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Lancet Oncol
; 15(10): 1119-28, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25153538
3.
Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA).
BMJ Open
; 13(4): e063242, 2023 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37076159
4.
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib.
J Comp Eff Res
; 7(9): 855-865, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29944008
5.
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
Cancer Chemother Pharmacol
; 79(3): 559-568, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28243683
6.
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Eur J Cancer
; 82: 27-33, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28646771
7.
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
J Thorac Oncol
; 12(10): 1552-1560, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28689043
8.
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
J Clin Oncol
; 34(34): 4079-4085, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27863201
9.
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
J Clin Oncol
; 28(13): 2144-50, 2010 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20368553
Resultados
1 -
9
de 9
1
Próxima >
>>